A Cancer Innovation Crisis? Misplaced Incentives Promote Marginal Benefits, JAMA Study Says
A study of oncology approvals since 2002 concludes that only 42% represented a “clinically meaningful improvement” in therapy. High prices encourage a “me-too” mentality that directs R&D investment to marginal indications, the authors assert.
You may also be interested in...
American Society of Clinical Oncology draft recommendations provide benchmarks for Phase III oncology drug trials, including a minimum 20% improvement in overall survival, with a higher bar for certain diseases.
Keeping Track: Enhertu Brings Anti-HER2 Therapy To Lung Cancer; Novaliq Platform Supports Two Dry Eye NDAs
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker